Walleye Trading
ALBO

Walleye Trading’s Albireo Pharma Inc ALBO Stock Holding History

Walleye Trading’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,800
Closed -$204K – 5674
2021
Q1 		$204K Buy
5,800
+5,600
+2,800% +$207K ﹤0.01% 3592
2020
Q4 		$8K Buy
+200
New +$7.27K ﹤0.01% 4469

Other funds holding ALBO

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Walleye Trading's ALBO Position: Q4 2022 in Review

Walleye Trading sold out of Albireo Pharma Inc (ALBO) in Q4 2022, closing a stake of 10,406 shares — an estimated $201K sold.

Walleye Trading first reported a position in ALBO in Q4 2020 and held it in 2 quarters. The position peaked at $201K in Q3 2022. 96 funds tracked by Wall St. Rank hold ALBO as of Q4 2022.

  • Walleye Trading reported no remaining Albireo Pharma Inc position as of Q4 2022 after selling out during the quarter.
  • Walleye Trading sold 10,406 Albireo Pharma Inc shares in Q4 2022, an estimated $201K.
  • Walleye Trading first reported a position in Albireo Pharma Inc in Q4 2020 and held it in 2 quarters.
  • Walleye Trading's Albireo Pharma Inc position peaked at $201K in Q3 2022.
  • 96 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q4 2022.

Based on Walleye Trading's 13F filing for Q4 2022, filed 14 Feb 2023.